Technical Analysis for CGEM - Cullinan Management, Inc.

Grade Last Price % Change Price Change
F 15.93 -0.56% -0.09
CGEM closed down 7.24 percent on Tuesday, November 12, 2024, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -0.56%
Fell Below 50 DMA Bearish -0.56%
180 Bearish Setup Bearish Swing Setup -0.56%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.56%
Outside Day Range Expansion -0.56%
Upper Bollinger Band Touch Strength -0.56%
Crossed Above 20 DMA Bullish -7.76%
Crossed Above 50 DMA Bullish -7.76%
Pocket Pivot Bullish Swing Setup -7.76%
Gapped Up Strength -7.76%

   Recent Intraday Alerts

Alert Time
Down 1% about 2 hours ago
Bearish 180 Entry about 2 hours ago
Non-ADX 1,2,3,4 Bearish Retracement Entry about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
10 DMA Support about 3 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cullinan Management, Inc. Description

Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell acute lymphoblastic leukemia; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. It has a collaboration agreement with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, LLC was founded in 2016 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Solid Tumors Immune System Antibodies Oncology Tumor Cancer Immunotherapy Monoclonal Antibody Cell Therapy Acute Myeloid Leukemia Non Small Cell Lung Cancer Therapies For Cancer Treatment Of Acute Myeloid Leukemia Oncology Therapies

Is CGEM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 30.1886
52 Week Low 7.6818
Average Volume 526,297
200-Day Moving Average 18.53
50-Day Moving Average 16.73
20-Day Moving Average 16.26
10-Day Moving Average 16.08
Average True Range 1.00
RSI (14) 47.64
ADX 11.86
+DI 22.19
-DI 14.24
Chandelier Exit (Long, 3 ATRs) 14.98
Chandelier Exit (Short, 3 ATRs) 18.14
Upper Bollinger Bands 17.45
Lower Bollinger Band 15.07
Percent B (%b) 0.4
BandWidth 14.67
MACD Line -0.12
MACD Signal Line -0.20
MACD Histogram 0.0808
Fundamentals Value
Market Cap 685.35 Million
Num Shares 42.8 Million
EPS -3.76
Price-to-Earnings (P/E) Ratio -4.26
Price-to-Sales 26.88
Price-to-Book 1.64
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.38
Resistance 3 (R3) 18.61 18.06 17.99
Resistance 2 (R2) 18.06 17.46 17.94 17.86
Resistance 1 (R1) 17.04 17.09 16.76 16.81 17.72
Pivot Point 16.48 16.48 16.35 16.37 16.48
Support 1 (S1) 15.47 15.88 15.19 15.23 14.32
Support 2 (S2) 14.91 15.51 14.79 14.18
Support 3 (S3) 13.89 14.91 14.05
Support 4 (S4) 13.66